With no significant adverse outcomes reported.

The medical investigators will continue steadily to monitor the individuals for re-occurrence of the condition at 3, 6, and 12 months. The study was carried out at two sites in the Democratic Republic of the Congo-Maluku and Vanga . T. Stephen Thompson, President and CEO of Immtech, said, We are pleased with the preliminary results of this study, which is incorporated in the upcoming randomized open label Stage III pivotal research to be carried out at multiple sites in Angola and the Democratic Republic of Congo. Immtech International, Inc. Is a pharmaceutical firm advancing the advancement of treatments for fungal attacks, malaria, tuberculosis, cancers, diabetes, Pneumocystis carinii pneumonia and tropical diseases, including African sleeping sickness and leishmaniasis..End Points The primary end point was mortality at 48 hours after randomization. Secondary end points were mortality at four weeks, neurologic sequelae at 4 and 24 weeks, episodes of hypotensive shock within 48 hours after randomization, and adverse events potentially related to liquid resuscitation . An end-point review committee, whose members were unaware of the procedure assignments, reviewed all deaths, neurologic sequelae, and adverse occasions.